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Background: Contrast-enhanced magnetic resonance imaging (CE-MRI) of the breast is highly sensitive for breast cancer
detection. Multichannel coils and 3T scanners can increase signal, spatial, and temporal resolution. In addition, the T1-
reduction effect of a gadolinium-based contrast agent (GBCA) is higher at 3T. Thus, it might be possible to reduce the
dose of GBCA at 3T without losing diagnostic information.
Purpose: To compare a three-quarter (0.075 mmol/kg) dose of the high-relaxivity GBCA gadobenate dimeglumine, with a
1.5-fold higher than on-label dose (0.15 mmol/kg) of gadoterate meglumine for breast lesion detection and characteriza-
tion at 3T CE-MRI.
Study Type: Prospective, randomized, intraindividual comparative study.
Population: Eligible were patients with imaging abnormalities (BI-RADS 0, 4, 5) on conventional imaging. Each patient
underwent two examinations, 24–72 hours apart, one with 0.075 mmol/kg gadobenate and the other with 0.15 mmol/kg
gadoterate administered in a randomized order. In all, 109 patients were prospectively recruited.
Field Strength/Sequence: 3T MRI with a standard breast protocol (dynamic-CE, T2w-TSE, STIR-T2w, DWI).
Assessment: Histopathology was the standard of reference. Three blinded, off-site breast radiologists evaluated the exam-
inations using the BI-RADS lexicon.
Statistical Tests: Lesion detection, sensitivity, speciﬁcity, and diagnostic accuracy were calculated per-lesion and per-
region, and compared by univariate and multivariate analysis (Generalized Estimating Equations, GEE).
Results: Five patients were excluded, leaving 104 women with 142 histologically veriﬁed breast lesions (109 malignant,
33 benign) available for evaluation. Lesion detection with gadobenate (84.5-88.7%) was not inferior to gadoterate
(84.5–90.8%) (P ≥ 0.165). At per-region analysis, gadobenate demonstrated higher speciﬁcity (96.4–98.7% vs. 92.6–97.3%,
P ≤ 0.007) and accuracy (96.3–97.8% vs. 93.6–96.1%, P ≤ 0.001) compared with gadoterate. Multivariate analysis demon-
strated superior, reader-independent diagnostic accuracy with gadobenate (odds ratio = 1.7, P < 0.001 using GEE).
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Data Conclusion: A 0.075 mmol/kg dose of the high-relaxivity contrast agent gadobenate was not inferior to a
0.15 mmol/kg dose of gadoterate for breast lesion detection. Gadobenate allowed increased speciﬁcity and accuracy.
Level of Evidence: 1
Technical Efﬁcacy: Stage 2
J. MAGN. RESON. IMAGING 2019;49:1157–1165.
Contrast-enhanced magnetic resonance imaging (CE-MRI)of the breast is highly sensitive for breast cancer
detection.1–3 Ongoing technological developments and rapid
system turnover have made multichannel coils and 3T scanners
broadly available for clinical use.4 Both these developments
increase the available signal that can be invested into increased
spatial and temporal resolution. In addition, the T1-reduction
effect of a gadolinium-based contrast agent (GBCA) is higher
at 3T compared with 1.5T, which translates into a higher
enhancement at T1-weighted imaging.
5 Both the higher signal-
to-noise ratio (SNR) and the higher sensitivity to GBCAs sug-
gest that it might be possible to reduce the dose of GBCA
without losing diagnostic information at 3T. This could have
relevant clinical implications, as GBCAs are expensive and are
associated with several adverse effects.6,7
Of the GBCAs available for breast MRI, gadobenate
dimeglumine (MultiHance; Bracco, Milan, Italy) is a linear,
ionic contrast agent characterized by a higher r1 relaxivity8
due to weak, transient interaction of the gadobenate contrast-
effective molecule with serum albumin.9 At 1.5T, this higher
r1 relaxivity translates into greater signal intensity, and thus,
better lesion visualization and signiﬁcantly better diagnostic
performance for breast MRI when compared intraindividually
with comparative standard relaxivity GBCAs at an equivalent
dose.10–14 Findings with gadobenate for MR applications
other than breast MRI have shown that a reduced dose pro-
vides image quality and diagnostic information similar to that
achieved with a 2-fold higher dose of a comparative
GBCA.15–19
Based on the available evidence, we hypothesized that
a reduced dose of gadobenate might also prove effective for
breast lesion detection and characterization when compared
with 1.5-fold higher than the on-label dose of a standard
relaxivity GBCA (gadoterate meglumine, Dotarem; Guer-
bet, Aulnay-sous-Bois, France) under otherwise identical
imaging conditions. Gadoterate meglumine is a macrocyclic,
ionic GBCA characterized by a lower relaxivity, osmolality,
and viscosity compared with gadobenate,20 and it is com-
monly used for breast MRI in several institutions,21 includ-
ing the one where this study was conducted. The aim of
this prospective, randomized, single-center study was to
intraindividually compare a three-quarter (0.075 mmol/kg
bodyweight) dose of gadobenate with a 1.5-fold higher-
than-on-label dose (0.15 mmol/kg bodyweight) of the stan-
dard relaxivity GBCA, gadoterate meglumine, with regard
to noninferiority for breast lesion detection and characteri-
zation at 3T.
Materials and Methods
The local Ethics Review Board approved this investigator-ini-
tiated, prospective, double-blinded, randomized, single-cen-
ter, controlled, crossover study and all regulatory approvals
were granted (EudraCT number 2011-005498-21). All pro-
cedures were in accordance with the ethical standards as laid
down in the 1964 Declaration of Helsinki and its later
amendments. An unrestricted grant from Bracco (Milan,
Italy) was provided to support the trial. All authors had full
control of all data and statistical results. All patients gave writ-
ten, informed consent. Patient enrollment occurred between
November 2014 and May 2015.
Patient selection and Standard of Reference
Consecutive women presenting to our tertiary care university hospi-
tal breast unit for the assessment of abnormal breast imaging ﬁnd-
ings (ie, classiﬁed as BI-RADS 0, 4, or 5) on mammography,
tomosynthesis, or ultrasound were eligible for this study. Excluded
were women below 18 years of age, women who were pregnant or
lactating, or who were undergoing radiation therapy, chemotherapy,
or anticancer hormonal therapy, and women with contraindications
to MRI (eg, pacemaker, metallic implants), a history of hypersensi-
tivity to gadolinium chelates, or who had chronic renal disease.
Women who were administered another contrast agent within
24 hours before the examination or underwent interventional proce-
dures between the two MRI examinations were also excluded.
Lesions considered suspicious after completion of both MRI
examinations underwent image-guided biopsy. Histopathology per-
formed within 1 week after the MRI examinations, from either
image-guided biopsy or surgical excision, was considered the stan-
dard of reference. For lesions classiﬁed as high-risk (lesions with an
uncertain malignant potential) after image-guided biopsy, surgical
excision was performed and the postsurgical results were considered
for the analysis.
Clinical data were collected (age, menopausal status, symp-
toms, indication for CE-MRI), as well as data on adverse reactions
following GBCA administration.
Image Acquisition
All examinations were performed using a 3T magnet (TIM Trio,
Siemens Healthcare, Erlangen, Germany) with a dedicated 16-channel
bilateral breast coil (Sentinelle, Invivo, Best, The Netherlands). Patients
were examined in the prone position using a standard protocol, as
recommended by international guidelines.22 Images were acquired in
the axial plane with the following sequences: a T2-weighted short tau
inversion recovery sequence (STIR, repetition time [TR] = 4800 msec,
echo time [TE] = 59 msec, inversion time [TI] = 230 msec, spatial
resolution 0.7 × 0.7 × 4 mm, interslice gap 20%, 44 slices, GRAPPA
factor 3, acquisition time [TA] 2:35); a T2-weighted turbo spin echo
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sequence (TSE, TR = 4630 msec, TE = 194 msec, spatial resolution
0.7 × 0.5 × 2.5 mm, interslice gap 20%, 65 slices, GRAPPA factor
3, TA = 2:48); and a readout-segmented, multishot, echo-planar,
imaging-based diffusion-weighted imaging (DWI) sequence
(RESOLVE, TR = 5800 msec, TE1 = 68 msec, TE2 = 116 msec, b
values 0 and 850 s/mm2, spatial resolution 1.4 × 1.4 × 4 mm, no
interslice gap, 28 slices, TA = 2:54). Contrast-enhanced T1-weighted
images were acquired using a view-sharing, 3D, time-resolved angiogra-
phy with stochastic trajectory, gradient echo sequence (TWIST, TR =
6.23 msec, TE = 2.95 msec, spatial resolution 0.9 × 0.9 × 1.1 msec,
140 slices, GRAPPA factor 3, temporal resolution 28 sec, one pre- and
10 postcontrast acquisitions). After the baseline (k-space mask) scan,
contrast agent was injected intravenously, without a delay, using an
automated injector (Spectris, Medrad, Pittsburgh, PA). Contrast agent
was administered intravenously at a rate of 3 ml/s, followed by a
15-ml saline ﬂush at the same rate.
Patients were randomized into two groups. One group
received gadoterate (0.15 mmol/kg) for the ﬁrst examination and
gadobenate (0.075 mmol/kg) for the second examination, while the
other group received the two GBCAs in reverse order. Each patient
received both contrast agents with the second examination per-
formed at least 24 hours after the ﬁrst examination to allow for clear-
ance of the ﬁrst agent from the body, but within 72 hours to assure
equivalent morphological and functional conditions.
The dose of gadobenate (0.075 mmol/kg) was based on ﬁnd-
ings from previous studies for other indications in which a lower dose
of gadobenate compared favorably with a higher dose of standard
relaxivity GBCA.15–18,23 The comparator agent gadoterate was chosen
primarily because it is the GBCA routinely used in our center for
breast MRI. A higher-than-on-label dose (0.15 mmol/kg) was selected
for this study for three reasons: 1) gadoterate has the lowest r1 relaxiv-
ity of all GBCAs at 3T (3.4 L·mmol−1·sec−1 compared with 5.35
L·mmol−1·sec−1 for gadobenate), and thus, might be expected to pro-
vide a relatively lower enhancement (8); 2) comparative studies with
gadobenate for other indications have revealed similar imaging perfor-
mance for a half-dose of gadobenate compared with a full dose of
gadoterate,17–19 as well as superior performance for a three-quarter
dose (0.075 mmol/kg) of gadobenate compared with a full dose of
gadoterate24; 3) an early interindividual comparative study revealed
not dissimilar imaging performance for a half-dose (0.05 mmol/kg) of
gadobenate compared with full and double doses (0.1 and 0.2 mmol/
kg) of the standard relaxivity GBCA gadopentetate dimeglumine
(Magnevist; Bayer, Berlin, Germany) for breast MRI.10 This dosage
set-up for our breast MR imaging protocol is in line with international
recommendations and current European clinical practice.4,25
Image Analysis
Three independent readers with 8–15 years of experience in breast
MRI evaluated all images off-site in three separate reading sessions.
Each reader was blinded to all clinical and radiological information
including the type of contrast agent. The reading sessions were per-
formed on a dedicated workstation (multimonitor imaging TeraRe-
con client server, TeraRecon AquariusNet server v. 4.4.5.36) with all
routine image-processing functions (eg, window/level, zoom, pan,
etc.) available.
In each of the ﬁrst two unpaired sessions, half the examina-
tions performed with gadoterate and half of those performed with
gadobenate were displayed and assessed in randomized order. The
entire examination was available for the readings. Readers were asked
to evaluate precontrast along with early and delayed postcontrast
sequences including subtracted images. T2-weighted sequences,
DWI, and nonsubtracted images were available for the evaluation if
the readers deemed it necessary. Readers were asked ﬁrst to assess
the technical adequacy of the images. Thereafter, for all technically
adequate images, each reader was asked to deﬁne the presence, num-
ber, location, size (≤5 mm / 6–10 mm / 11–20 mm / >20 mm),
and nature (benign/high-risk/malignant) of all enhancing lesions
according to the BI-RADS lexicon.26 The presence and location of
lesions in this Obuchowski Level III setup27 were deﬁned using a
scheme (Supplemental Material, Fig. a) that divided the breast into
ﬁve regions: upper-outer, upper-inner, lower-outer, lower-inner, and
retroareolar. Lesions classiﬁed as BI-RADS >3 were considered suspi-
cious. Diagnostic conﬁdence was assigned to BI-RADS scores rang-
ing from 1 (minimal) to 5 (maximal). Breast density (amount of
ﬁbroglandular tissue [FGT]; a, almost entirely fat; b, scattered FGT;
c, heterogeneous FGT; d, extreme FGT) and background parenchy-
mal enhancement (BPE; a, minimal; b, mild; c, moderate; d,
marked) were also assessed according to the BI-RADS lexicon.26
In the third session, gadobenate and gadoterate examinations
of the same patient were placed side-by-side in randomized order to
comparatively assess examination quality. In this session, readers
expressed a preference for one image set or the other in terms of
lesion conspicuity and lesion border delineation relative to surround-
ing normal breast tissue (each evaluation based on a ﬁve-point scale
from –2 to + 2, with 0 indicating equality of the two examinations),
and overall diagnostic preference based on available radiological
information for diagnosis or clinical management (a seven-point scale
from –3 to + 3, with 0 indicating equality of the two examinations).
Finally, an on-site radiologist performed lesion-tracking. Only
lesions detected by at least one reader for one contrast agent, and for
which the standard of reference was available (histology obtained
with image-guided biopsy or surgical excision), were included. The
on-site reader assessed whether the same lesions had concordantly
been identiﬁed by all readers and with both contrast agents. If a
reader missed a lesion, the classiﬁcation was considered incorrect for
that reader. Likewise, if a malignant lesion was detected by a reader,
but classiﬁed as BI-RADS 2 or 3, then the classiﬁcation was consid-
ered incorrect for that reader. In case of doubt, a second on-site
reader was consulted.
Statistical Analysis
The patient sample size was based on the primary efﬁcacy analysis,
ie, the noninferiority of 0.075 mmol/kg gadobenate compared with
0.15 mmol/kg gadoterate for the detection of malignant breast
lesions. The noninferiority margin was set at –10%, with a study
power of 85%. Lesion detection was calculated for all lesions identi-
ﬁed, regardless of the BI-RADS classiﬁcation. Detection rate (lesions
identiﬁed / total lesions included in the study), sensitivity, speciﬁc-
ity, and diagnostic accuracy were calculated separately for each reader
and for each contrast agent, and compared using the McNemar test.
Analysis was performed both per-lesion and per-region. The per-
region analysis (Obuchowksi Level III27 considered the presence or
absence of suspicious ﬁndings (BI-RADS 4 and 5) for each of the
ﬁve predeﬁned regions of each breast. Logistic regression model was
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performed to determine if lesion size, FGT, and type of lesions were
predictors for the sensitivity, speciﬁcity, and accuracy of the lesion
characterization. Finally, Generalized Estimating Equations (GEE)
were used to evaluate the effect of readers and contrast agent on
diagnostic accuracy. Fisher’s exact-test was used to test for differences
in the false-positive (FP) rate between readers and GBCAs. Wilcox-
on’s signed rank test was used to evaluate the differences in the
paired assessment. Interreader agreement about lesion nature (benign
vs. malignant) was assessed using kappa statistics. All statistical tests
were two-sided at the P < 0.05 level of signiﬁcance.
Results
Patient Characteristics and Safety Analysis
A ﬂow chart with subject enrollment and dropout is shown
in Fig. 1. The ﬁnal population included 104 patients from
26 to 84 years of age (mean ± standard deviation:
51.7 ± 13.45 years). Clinical data and indications to perform
breast CE-MRI, as well as information on breast density and
background parenchymal enhancement, are given in Tables 1
and 2. A total of 142 histologically veriﬁed breast lesions
(109 malignant, 33 benign) were identiﬁed (Table 3).
No moderate or severe adverse events were reported.
Only one minor adverse event (self-limiting urticaria) was
reported after gadoterate injection.
Detection Rate
A three-quarter dose of gadobenate was not inferior to a 1.5-fold
higher-than-on-label dose of gadoterate for breast lesion detection
for any reader (P ≥ 0.165; Table 4). Lesion detection was high,
ranging from 84.5–88.7% for gadobenate and from 84.5–90.8%
for gadoterate. Five of the 25 lesions (20%) not detected by at
least one reader with gadobenate and ﬁve of the 23 (22%) lesions
not detected with gadoterate were malignant (P > 0.06). Two
invasive lobular carcinomas and three ductal carcinomas in situ
were missed by at least one reader with both contrast agents.
Diagnostic Performance: Per-Lesion Analysis
In the 0.075 mmol/kg gadobenate group, higher sensitivity,
speciﬁcity, and diagnostic accuracy were observed; however,
only the higher speciﬁcity reported by Reader 1 was statisti-
cally signiﬁcant (P = 0.034) (Table 4).
Lesions incorrectly classiﬁed by at least one reader are
described in the Supplemental Material (Table a). Multivari-
ate analysis showed that the FP rate was not inﬂuenced by
the background parenchymal enhancement (BPE, P > 0.319).
This was true despite a generally higher BPE in the examina-
tions performed with gadoterate (moderate or marked BPE
present in 34.6–68.2% of the examinations with gadoterate
vs. 29.8–57.7% with gadobenate [Table 2]).
Multivariate analysis showed that 0.075 mmol/kg gadobe-
nate was superior to 0.15 mmol/kg gadoterate for tumor charac-
terization (odds ratio [OR] = 1.43, P = 0.003) and that this
result was independent of the readers. Interreader agreement on
FIGURE 1: Flow chart showing the inclusion process.
Examination was considered not technically adequate when the
target lesion was outside the ﬁeld of view, or reconstruction
artifacts in the postcontrast images were present in one of the
examinations, which made the images of not sufﬁcient quality
for evaluation according to at least one reader.
TABLE 1. Clinical Data and Indications to Perform
Breast MRI
Number of patients (%)
Menopausal status
Premenopausal 47 (45.2)
Perimenopausal 3 (2.9)
Postmenopausala 54 (51.9)
Symptoms
No symptoms 55 (52.9)
Palpable lesion 35 (33.7)
Skin thickening 13 (12.5)
Nipple retraction 4 (3.8)
Nipple discharge 3 (2.9)
MRI indications
Staging of a highly suspected breast cancer 66 (63.5)
Evaluation of a suspicious lesion 15 (14.4)
Evaluation of equivocal ﬁndings 23 (22.2)
aPhysiological and postsurgical (ie, ovariectomy) menopause were
considered together.
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lesion nature was moderate for both contrast agents (κ = 0.398
with gadobenate and κ = 0.370 with gadoterate).
Logistic regression showed no effect of FGT on readers’
accuracy (P ≥ 0.256 with gadobenate and P = 0.133 with
gadoterate).
Lesion size was a signiﬁcant positive predictor in both
groups for all three readers, with signiﬁcantly better accuracy
for larger lesions noted by Reader 1 for gadoterate
(P = 0.004) and by Reader 2 for both gadobenate and gado-
terate (P = 0.028 and P = 0.003, respectively).
Lesion type had no effect on accuracy for Reader 1
(P = 0.341 with gadobenate and P = 0.133 with gadoterate)
and Reader 2 (P = 0.673 with gadobenate and P = 0.078 with
gadoterate). Reader 3 reported higher accuracy for nonmass
lesions with both contrast agents (P = 0.041 with gadobenate
and P = 0.008 with gadoterate).
Diagnostic Performance: Per-Region Analysis
Per-region analysis was performed by dividing each breast
into ﬁve regions (Supplemental Material Fig. a) to give 1040
regions in total.
In the per-region analysis (Table 5), all readers reported
better performance with 0.075 mmol/kg gadobenate group
than with 0.15 mmol/kg gadoterate. Signiﬁcant differences
were found by Reader 2 for sensitivity (P = 0.011) and by all
three readers for speciﬁcity and accuracy (P < 0.007 and P <
0.001, respectively).
The number of FP cases was lower in the 0.075 mmol/
kg gadobenate group than in the 0.15 mmol/kg gadoterate
group for all three readers: 31 (3.0%) vs. 63 (6.1%);
18 (1.7%) vs. 29 (2.8%); and 11 (1.1%) vs. 23 (2.2%) for
Readers 1, 2, and 3, respectively.
The GEE model conﬁrmed the superior diagnostic
accuracy with gadobenate (OR = 1.7, P < 0.001), with only
minor differences between readers. In the model adjusted for
random and ﬁxed reader effects, the differences between both
contrast media groups were conﬁrmed. Examples of the con-
trast enhancement achieved with both agents and the better
diagnostic performance achieved in the 0.075 mmol/kg gado-
benate group are shown in Figs. 2 and 3.
TABLE 2. Distribution of Fibroglandular Breast Tissue (FGT) and Background Parenchymal Enhancement (BPE), for
Each Reader and Contrast Agent
Reader 1 Reader 2 Reader 3
Gadobenate
No. (%)
Gadoterate
No. (%)
Gadobenate
No. (%)
Gadoterate
No. (%)
Gadobenate
No. (%)
Gadoterate
No. (%)
FGT a 45 (43.3) 40 (38.5) 18 (17.3) 19 (18.3) 4 (3.8) 5 (4.8)
FGT b 27 (26.0) 30 (28.8) 20 (19.2) 21 (20.2) 39 (37.5) 40 (38.5)
FGT c 18 (17.3) 18 (17.3) 37 (35.6) 33 (31.7) 48 (46.2) 45 (43.3)
FGT d 14 (13.5) 16 (15.4) 29 (27.9) 31 (29.8) 13 (12.5) 14 (13.5)
BPE a 44 (42.3) 37 (35.6) 40 (38.5) 36 (34.6) 21 (20.2) 12 (11.5)
BPE b 29 (27.9) 31 (29.8) 16 (15.4) 14 (13.5) 23 (22.1) 21 (20.2)
BPE c 20 (19.2) 20 (19.2) 17 (16.3) 18 (17.3) 26 (25.0) 30 (28.8)
BPE d 11 (10.6) 16 (15.4) 31 (29.8) 36 (34.6) 34 (32.7) 41 (39.4)
TABLE 3. Histology of the 109 Malignant and
33 Benign Lesions Included in the Analysis
Histology
Number of
lesions (%)
Malignant
Invasive carcinoma NST 66/109 (60.6)
Ductal carcinoma in situ 23/109 (21.1)
Invasive lobular carcinoma 16/109 (14.7)
Othersa 4/109 (3.6)
Benign
Fibrocystic changes 19/33 (57.6)
Papilloma without atypias 5/33 (15.2)
Fat necrosis 4/33 (12.1)
Sclerosing adenosis without atypias 3/33 (9,1)
Fibroadenoma 2/33 (6.0)
NST: nonspecial type.
aOne medullary carcinoma, one mucinous carcinoma, one inva-
sive ducto-lobular carcinoma, one secretory carcinoma.
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Conﬁdence and Paired Assessment
Reader conﬁdence in BI-RADS assessment was high
(median = 4, for all readers), regardless of the contrast agent
used. In the paired assessment (Supplemental Material
Table b), the two examinations were considered equal in
quality in more than 50% of cases (ranging from
52.4–91.3% depending on the reader and the endpoint) by
all three readers For the remaining cases, the readers preferred
0.15 mmol/kg gadoterate in 4.3–25.2% of the cases and
0.075 mmol/kg gadobenate in 3.9–22.3% of the cases with
no signiﬁcant difference in terms of preference (P > 0.392).
Discussion
Our study shows that a three-quarter (0.075 mmol/kg) dose
of gadobenate is not inferior to a 0.15 mmol/kg dose of
gadoterate for breast lesion detection. Speciﬁcally, three
blinded, unafﬁliated readers assigned fewer FP ratings with
the reduced dose of gadobenate, which resulted in small, but
highly signiﬁcant beneﬁt in speciﬁcity for lesion characteriza-
tion, without a loss of sensitivity for lesion detection. A clear
clinical impact of this ﬁnding is a lower number of unneces-
sary breast biopsies of benign breast tumors, and, conse-
quently, fewer short-term follow-up examinations and lower
costs. Importantly, all three readers considered the images
with both agents to be of comparable quality in most cases,
FIGURE 2: Invasive breast cancer in the left breast of a 46-year-old
woman. Postcontrast, subtracted, T1-weighted 3D gradient echo
images (TR 6.23 msec, TE 2.95 msec) acquired 1 minute (a) and
5minutes (b) after the administration of 0.15 mmol/kg of gadoterate
meglumine. A moderate background parenchymal enhancement
was present in both examinations. The arrows indicate an area of
clumped nonmass enhancement, which is difﬁcult to differentiate
from background parenchymal enhancement (BPE). Two of the
three readers classiﬁed this area as BI-RADS 2 (benign ﬁnding).
Postcontrast, subtracted, T1-weighted 3D gradient echo images
acquired 1 minute (c) and 5 minutes (d) after the administration of
0.075 mmol/kg of gadobenate dimeglumine. The arrows indicate
the area of clumped nonmass enhancement in the early postcontrast
sequence, which is clearly visible despite the BPE in the late
postcontrast sequence. Two of the three readers classiﬁed this area
as BI-RADS 4 (suspicious). Asterisk indicates a vessel.
FIGURE 3: MRI of the breast in a 39-year-old woman. Histology
revealed an area of pseudoangiomatous stromal hyperplasia in
the right breast. Postcontrast, subtracted, T1-weighted 3D
gradient echo images (TR 6.23 msec, TE 2.95 msec) acquired
1 minute (a) and 5 minutes (b) after the administration of
0.15 mmol/kg of gadoterate meglumine. A minimal background
parenchymal enhancement was present in both examinations.
The arrows indicate an area of heterogeneous nonmass
enhancement. The readers classiﬁed the enhancement as BI-
RADS 4 (suspicious). Postcontrast, subtracted, T1-weighted 3D
gradient echo images acquired 1 minute (c) and 5 minutes (d)
after the administration of 0.075 mmol/kg of gadobenate
dimeglumine. The arrows indicate the area of nonmass
enhancement, which presented with a weak enhancement and
was classiﬁed by the readers as BI-RADS 2 (benign ﬁnding).
Asterisk indicates a vessel.
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with neither agent demonstrating a signiﬁcant advantage over
the other for any qualitative endpoint.
Previous intraindividual crossover studies at 1.5T com-
pared gadobenate with gadopentetate at an equivalent
approved dose of 0.1 mmol/kg bodyweight.10–13 Martincich
et al13 showed a reduction in the rate of cancer misdiagnosis
when comparing the same dose of gadobenate and gadopente-
tate. In addition, two studies by Pediconi et al demonstrated
that gadobenate leads to an improved diagnostic performance
compared with gadopentetate.11,12 The superior diagnostic
performance observed was ascribed to the greater signal inten-
sity enhancement achievable with gadobenate due to its
higher relaxivity. A more recent study at 1.5T compared
gadobenate with the macrocyclic GBCA gadobutrol
(Gadovist; Bayer) at an equivalent dose (0.1 mmol/kg)28 and
reported noninferiority for gadobutrol with regard to lesion
detection and sensitivity for characterization based on ﬁnd-
ings from two blinded readers.
Our study demonstrates that it is feasible to reduce the
dose of the administered GBCA at 3T without losing impor-
tant information in terms of lesion detection and sensitivity.
This seems to be particularly relevant considering the growing
concern over gadolinium deposition in the brain following
GBCA administration.29 In this regard, it is worth bearing in
mind that gadolinium retention has been observed in both
the brain and other body tissues after administration of both
linear and macrocyclic GBCAs,30 and as yet there is no evi-
dence of any detrimental clinical signs or symptoms.29,31,32
Based on our ﬁndings and those of others,11–14 in the absence
of deﬁnitive data regarding the potential risk of gadolinium
retention (or lack thereof ), it would seem prudent to consider
a lower dose of gadobenate (ie, less administered gadolinium),
at least for diagnostically challenging indications such as
locoregional staging and problem-solving. Currently, a large-
scale prospective randomized phase II trial is under way to
evaluate a gadobenate-based MRI protocol as an additional
screening test in women with dense breasts.33 If this trial
proves successful, our ﬁndings may prove useful in terms of
dose optimization.
A further advantage of using a reduced dose of GBCA
might be a reduction in BPE, an effect that may be pro-
nounced at 3T due to the inherently higher sensitivity to
GBCAs.5 A reduction in BPE facilitates lesion characteriza-
tion and may be one reason for the increased speciﬁcity of
the readers in the reduced-dose group in our study. In addi-
tion to a BPE reduction, a lower GBCA dosage will also lead
to a lower contrast enhancement of suspicious lesions. Due
to our speciﬁc study design, we cannot answer whether it is
generally possible to reduce GBCA dosages at 3T without
reducing sensitivity. Importantly, all three readers consid-
ered the images from both agents to be of comparable qual-
ity in most cases, with neither agent demonstrating a
signiﬁcant advantage over the other for any qualitative
endpoint. In studies that have compared equivalent
doses11,13 at 1.5T, readers preferred examinations performed
with gadobenate, a ﬁnding that does not seem to apply at
3T comparing different doses.
Our study has several limitations. First, the dose of
gadoterate used (0.15 mmol/kg) was higher than the recom-
mended dose (0.1 mmol/kg). This has two possible conse-
quences for speciﬁcity: a higher dose will lead to both an
increased lesion enhancement and higher BPE, both likely
leading to a higher FP rate. A detrimental effect of BPE on
FP rates, however, could not be corroborated by multivariate
analysis. A side-by-side evaluation of examinations with both
agents revealed no differences in contrast enhancement or
image quality; thus, there are no obvious reasons for a higher
FP rate with gadoterate, based on contrast enhancement.
Although our data do not allow us to answer the question
whether a reduced contrast medium dose will generally
improve breast MRI speciﬁcity at 3T, we deem this quite
likely. However, trying to improve speciﬁcity may lead to
decreased sensitivity. Although the reduced dosage of the
high-relaxivity contrast agent gadobenate achieved sensitivities
equal to even a higher-than-on-label dose of gadoterate, our
data do not allow drawing conclusions about contrast media
with lower relaxivity in this respect. A lower dose of a low-
relaxivity contrast medium may lead to a lower lesion detec-
tion rate and poorer diagnostic performance. Second, our
study was a single-center observational study performed in
patients who presented with suspicious ﬁndings on conven-
tional imaging. Only cases for which a histological examina-
tion was performed were included, leading to greater selection
of more suspicious or complicated lesions, and to a higher
rate of malignancy in our cohort. Third, we did not perform
kinetic analysis and did not compare the dynamic
enhancement-time curves for gadobenate and gadoterate. This
would be of interest for further studies but was considered
beyond the scope of this analysis. Fourth, the lack of long-
term follow-up suggests the possibility—albeit small—that
single FN ﬁndings were missed. Consequently, the study
design is associated with a minor risk of overestimating sensi-
tivity and a moderate risk of underestimating speciﬁcity.
Finally, we considered noninvasive ductal carcinoma in situ
as a malignant lesion for this study, which is generally in line
with the surgical management.
In conclusion, a three-quarter dose (0.075 mmol/kg) of
high-relaxivity gadobenate is not inferior to a 1.5-fold higher-
than-on-label dose (0.15 mmol/kg) of lower relaxivity gadote-
rate for breast lesion detection. Moreover, the reduced dose
of gadobenate allows improved lesion characterization by low-
ering the number of FP reports, thus leading to increased
speciﬁcity and diagnostic accuracy. The use of a reduced dose
of gadobenate would seem particularly beneﬁcial for diagnos-
tically challenging indications, such as locoregional staging
and problem-solving cases.
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